(2 major criteria or 1 major criterion plus 2 minor criteria or 4 minor criteria) for diagnosis of ARVC (Table 1; Table I in the Data  Supplement) . 2, 13 All patients had a minimum 1 year of follow-up after their last ablation procedure, and no patient was lost at follow-up. The study conformed to the institutional guidelines of the University of Pennsylvania Health System, and all patients gave written informed consent to have the data collected and prospectively entered in a database for research purposes.
Electrophysiological Evaluation and Instrumentation
AADs were routinely discontinued ≥5 half-lives before the procedure; amiodarone was discontinued at least 3 days before the procedure. Recurrent unstable arrhythmias necessitated continued AAD therapy in selected patients at the time of the procedure. All patients underwent the procedure in the fasting state. Conscious sedation was used whenever possible. General anesthesia was used when necessary at the discretion of the operator or anesthesiologist involved in the procedure for ventilation, oxygenation, or patient comfort and during epicardial mapping and ablation procedures. Catheters were placed into position in the heart using fluoroscopic guidance. A standard transvenous 6F quadripolar catheter with 5-mm interelectrode distance (Bard Inc., Delran, NJ) was placed at the RV apex. An 8F 64-element phased-array intracardiac echocardiography catheter (AcuNav, Acuson, Mountain View, CA) was used routinely for cases after year 2005 to assist catheter manipulation, to assess tissue-catheter contact, and to monitor for complications. In 52 (84%) patients, a deflectable 3.5-mm open irrigated tip catheter (NaviStar ThermoCool, Biosense Webster, Diamond Bar, CA) was used for mapping and ablation; a bidirectional closed irrigated ablation catheter (Chilli, Boston Scientific, Natick, MA) was used in 2 (3%) patients. In the remaining 8 (13%) patients (all before 2002), a nonirrigated 4-mm tip ablation catheter (NaviStar, Biosense Webster) was used. The programmed ventricular stimulation protocol to induce VT included up to triple extrastimuli from at least 2 right ventricular sites with at least 2 drive cycle lengths.
Endocardial Voltage Mapping
A detailed electroanatomic map of the endocardial RV surface was performed during sinus or paced rhythm maintaining a fill threshold of 20 mm to ensure adequate sampling and representation of the entire endocardial surface area. The bipolar signals were filtered at 30 to 400 Hz (CARTO V.9 and V.7 systems, Biosense Webster, Inc) or 16 to 500 Hz (CARTO-3 system, Biosense Webster, Inc) and were displayed at 100 mm/s speed. The peak-to-peak signal amplitude of the bipolar electrogram was measured automatically and confirmed during manual review. The electrogram signals were displayed as color gradients on a 3-dimensional computerized bipolar voltage map. Tricuspid valvular sites were identified by the fluoroscopic catheter tip positions at the ventricular base with discrete bipolar recordings that demonstrated both sharp atrial and ventricular signals of approximately equal amplitude and confirmed with the use of direct valve visualization with intracardiac echocardiography (for cases after year 2005). The pulmonic valve was carefully identified by passing the mapping catheter into the pulmonary artery and slowly withdrawing it until an RV electrogram was identified, and RV capture was possible and confirmed with the use of direct visualization of the valve with intracardiac echocardiography (for cases after year 2005). Valvular sites were given a location only tag to preclude their influence on the voltage map color. Careful attention was paid to record multiple endocardial electrograms around valvular structures. Intracavitary points were identified as abrupt indentations on the endocardial shell contour with associated sudden reductions in signal slew rate and were appropriately redacted from the voltage maps. Reference values for identifying abnormal endocardial bipolar electrogram signal amplitude in the RV were defined according to previously established criteria.
14 A signal amplitude of >1.5 mV was categorized as normal and was represented in the electroanatomic map (CARTO) by purple color. Abnormal endocardium was represented by the nonpurple range of colors, with the most abnormal signal amplitude, arbitrarily defined as dense scar (consistent with signal amplitude <0.5 mV), represented by red color.
Epicardial Mapping
Epicardial access was obtained with the techniques described by Sosa et al. 15 An inferior approach to the pericardial sac was used to prevent puncture or laceration of the dilated RV. Particular caution was exercised to avoid inadvertent puncture of the liver, which may 
WHAT IS KNOWN
• In patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and recurrent ventricular tachycardia (VT) endo-epicardial substrate modification with catheter ablation has been shown to achieve good VT control during shortterm follow-up, but long term follow-up data is limited.
• Because of previous poor outcomes with endocardial only ablation, epicardial ablation is now routinely considered, but whether it is necessary for all patients is debated.
WHAT THE STUDY ADDS
• In this study, epicardial ablation was used when VT remained inducible or recurred after endocardial ablation. VT free survival was 71% with a mean follow-up of 56 months, with an additional 15% experiencing only a single VT recurrent episode, and with no patient receiving long-term amiodarone therapy.
• Approximately half of patients required more than one procedure and 37% received only endocardial ablation.
• In patients with ARVC, long term VT control can be achieved in the majority of cases with a strategy of endocardial ablation with adjuvant epicardial VT ablation.
be enlarged in patients with ARVC because of increased right heart pressures. The access was performed on the left of the xiphoid process maintaining an entry angle as shallow as possible (tangential to the lower border of the ribs) and compressing the epigastric region to minimize the risk of intra-abdominal organ perforation. An 8F sheath (or a deflectable sheath) was introduced into the pericardial space, and the mapping/ablation catheter was advanced through the sheath. Detailed voltage mapping focused on the entire RV and extended over the left ventricular surface. The fill threshold for RV epicardial mapping was also maintained at 20 mm, and mapping over the RV was continued until all areas were sampled. The epicardial boundaries of the RV were defined as being opposite the endocardial anatomic shell. More rigid voltage cutoff criteria were used when bipolar signals on the RV epicardium were analyzed to limit the influence of epicardial fat and coronary vasculature. The reference value for defining abnormal electrograms in the epicardium was <1.0 mV, as previously reported. 9 Dense scar was also arbitrarily defined as <0.5 mV for display purposes for the epicardial electroanatomic maps. To further limit the influence of epicardial fat and small-vessel coronary vasculature (ie, vessels that cannot be directly appreciated by coronary angiogram) on the low-voltage region, the contiguous low-voltage electrograms had to demonstrate not only a low amplitude but also signals with discrete late potentials (recorded after the QRS of the surface ECG) and demonstrate broad multicomponent or split signals within the boundary of the defined contiguous low-voltage abnormality. Signals larger than 1.0 mV that also demonstrated abnormal, multicomponent, split or late signal were also tagged and if adjacent to confluent areas of low voltage typically included in substrate-based ablation targets. Beginning in 2008, endocardial unipolar voltage mapping was used to identify a high likelihood of epicardial substrate abnormality in patients with no or modest endocardial bipolar voltage abnormalities as previously described. 16 Briefly, a unipolar signal cutoff of <5.5 mV for recordings from the RV free wall identified a high likelihood of adjacent confluent epicardial bipolar signal abnormalities.
Catheter Ablation
The 12-lead ECG morphology of all spontaneous VTs (when available) and the intracardiac near-field and far-field electrograms of the implantable cardioverter defibrillator (ICD) were collected and compared with the inducible VT(s) during the procedure. For hemodynamically tolerated VT, activation and entrainment mapping were used for tachycardia localization. The defined site of origin and target for more directed ablation demonstrated presystolic activity and entrainment with concealed fusion and a return cycle length within 30 ms of the VT cycle length. Termination with focal radiofrequency energy application was associated with these criteria and confirmed the origin of the tachycardia. For VTs that were not mappable, the site of origin was approximated using pace mapping to reproduce the VT QRS complex and to identify sites with a long stimulus to QRS interval. Limited activation and entrainment information were used to corroborate the pace map information when possible. Radiofrequency ablation was guided on the basis of all mapping data, including the location of the best pace map, the location of valvular anatomic boundaries, and detailed characterization of the substrate defined by voltage mapping, including definition of all signals with discrete split or late potentials recorded during sinus rhythm or with RV apical pacing and the identification of discrete higher voltage channels in sinus rhythm in the low-voltage region. 9 Characteristically, linear lesions were placed through the site of the best pace map with long stimulus to QRS (>30 ms) or through channels and transected the abnormal myocardium, extending from the valve annulus to normal myocardium (>1.5 mV in the endocardium; Figure 1 ). The ablation strategy included targeting markedly abnormal fractionated split and late potentials, with a specific emphasis on abnormal potentials recorded within a 2-to 3-cm radius of the site of origin, defined by entrainment mapping or the best pace map as typically producing clusters of radiofrequency lesions targeting these potentials with the end point of signal modification or elimination in addition to any linear lesion. This more extensive targeting of the substrate was the routine on the epicardium, where linear lesions anchored to the valve annulus were limited by proximity to the right coronary artery ( Figure 2 ). Epicardial radiofrequency lesions always avoided large coronary vessels by at least 1 cm based on cine angiography. If monomorphic VT inducibility persisted after targeting all spontaneous and initially inducible VT, residual VT morphologies were remapped using the techniques described above. More extensive substrate ablation was typical when multiple VT morphologies were inducible as was characteristic of most patients ( Figure 3 ).
Radiofrequency energy application with the 4-mm standard catheter was routinely set at 50 W and 55°. Open irrigated ablation targeted a maximum temperature of 42° and a maximum impedance drop of 12 to 15 Ohms with an output of 20 to 50 W. Closed irrigated ablation was set to deliver for 20 to 50 W, targeting a maximum temperature of 45° and a maximum impedance drop of 12 to 15 Ohms. Lesion duration was typically set for 60 to 90 s but was further increased to ≥3 minutes in duration at sites associated with transient suppression of VT with monitoring to confirm stable impedance drop.
The amount of fluid in the epicardial space associated with the open irrigated catheter mapping and ablation was monitored with intracardiac echocardiography and continuous intra-arterial blood pressure monitoring for evidence of hypotension. At the end of the ablation procedure, 2 to 3 mg/kg of triamcinolone was routinely administered intrapericardially. A pigtail catheter was routinely left in place in the pericardial sac and removed within 24 hours after the 
End Points and Follow-Up
The study end point was freedom from any recurrent sustained ventricular arrhythmias (ie, monomorphic VT, polymorphic/pleomorphic VT, and ventricular fibrillation) after the last procedure. The acute procedural end point evolved over the years and consisted of noninducibility of any clinical VTs and of any inducible VTs (excluding nonclinical VTs with a cycle length <280 ms) for the earlier experience with ENDO-only ablation and of noninducibility of any VT (excluding very fast [<240 ms] nonclinical VTs/ventricular flutter with a sine wave QRS complex and no discrete isoelectric baseline) for patients who underwent extensive ENDO-EPI substrate ablation. The acute efficacy was assessed on the basis of inducibility of VT at the end of the ablation procedure with a consistent stimulation protocol (up to triple extrastimuli from up to 2 ventricular sites with at least 2 drive cycle lengths) and at the time of repeat programmed stimulation before hospital discharge typically noninvasively at a single RV site via the ICD system (48 patients) routinely after year 2000. In 2 patients, a repeat invasive electrophysiological study using multisite stimulation was performed. Long-term clinical follow-up included surface ECG recordings at the time of symptoms and routine, every 4 to 6 months, ICD interrogation to document arrhythmia recurrences. Device programming after VT ablation has been consistent throughout the years and always included a VT zone, with rates able to detect (and treat if still inducible) the slowest clinical and induced VT. The effect of additional AAD therapy on cycle length slowing was also taken into account to avoid underdetection of VT.
The device programming strategy was uniform for both the ENDOonly and ENDO-EPI group. When longitudinal office follow-up visits were not performed after the 1-year visit, telephone interviews were performed with patients, referring physicians and family members at 6-and 12-month interval to confirm the absence of arrhythmias with review of stored device electrogram information whenever reported therapy was indicated.
Statistical Analysis
Descriptive statistics are reported as mean±SD for continuous variables, median and quartiles for skewed distributions, and absolute frequencies and percentages for categorical variables. Long-term arrhythmia-free survival was reported as crude event rates and assessed through a time-to-event analysis by the Kaplan-Meier method. Univariate and multivariable Cox proportional hazard regression was used to identify baseline clinical variables predictive of VT recurrence over follow-up. All statistical tests were 2-sided, and a P <0.05 was considered statistically significant. Data were analyzed by the STATA 12.1 statistical software (Stata Corporation, TX).
Results

Baseline Characteristics
The study group included 62 patients (age 39±15 years, 45 males, 58 with an ICD; 47 of which were implanted before the catheter ablation; Table 1 ). All patients with an ICD had history of recurrent VT, leading to either multiple ICD interventions or recurrent symptomatic episodes of nonsustained VT/frequent premature ventricular contractions. All patients met Task Force criteria for ARVC after extensive clinical evaluation (Table I in the Data Supplement). The 4 patients who were discharged after ablation without an ICD initially presented with recurrent episodes of sustained monomorphic VT associated with palpitations and dizziness; an ICD had been previously recommended in all 4 patients.
On clinical presentation, none of the patients had a known family history of proven ARVC. Genetic testing was available in 20 of 62 (32%) patients. Genetic testing was positive for a class I or II variant (most commonly involving the plakophilin and desmoglein genes) in 7 (35%) cases. On transthoracic echocardiography (62/62, 100%) and cardiac magnetic resonance (39/62, 63%), most (57/62, 92%) patients had evidence of classical structural and functional abnormalities of the RV. In total, 34 of 39 (87%) patients had cardiac magnetic resonance abnormalities diagnostic for ARVC including (1) The ECG documented clinical ventricular arrhythmias with a left bundle branch block morphology in all patients. Before ablation, 54 of 62 (87%) patients had failed antiarrhythmic medications (mean, 2.4 AADs; median, 2 AADs) with recurrent VT episodes. This included 25 patients who failed class 1 or 3 AADs (excluding amiodarone), 29 (47%) who failed amiodarone, and 8 β-blockers only or no antiarrhythmic medication (Figure 4) . A total of 29 patients had a prior ablation at outside institutions. All but one of these ablations were ENDO-only.
Procedural Findings
During the study period, a total of 121 procedures were performed in 62 patients (median, 2 [range, [1] [2] [3] [4] [5] procedures per patient), with 23 (37%) receiving ENDO-only procedures and 39 (63%) more extensive substrate ablation, which included ENDO and adjunctive EPI procedures because of either VT recurrence after ENDO-only ablation (n=13) or when the acute procedural end point (noninducibility at programmed stimulation) was not met. Of the 62 patients, 28 (45%) underwent a single procedure. Of the 34 patients with repeat procedures, 9 had all of their procedures during a single hospitalization and, as mentioned, 13 patients had an ENDO-EPI ablation procedure following recurrence after ENDO ablation. Of the remaining 12 patients, the last ablation procedure was performed an average of 25.5±29.8 months (range, 1 to 99 months) after the prior ablation and was followed by an average of 86.8±61.1 months (range, 19 to 187 months) of additional follow-up. The number of distinct inducible and clinical VTs that were recorded and targeted for ablation throughout the study duration was a median of 4 per patient (range, 1-14). In 10 (16%) patients, frequent premature ventricular contractions were also targeted during the ablation procedure(s) because of history of symptoms associated with premature ventricular contractions and morphology mimicking the clinical sustained VT(s).
All patients had evidence of ENDO and EPI electroanatomic low-voltage areas consistent with scar, with predominant locations in the perivalvular regions (peritricuspid and RV infundibulum) typically extending from the valve annuli to include extensive areas of the RV anterior and inferior free wall. The RV apex (ENDO and EPI) was neither a site of extensive abnormal electroanatomic substrate nor the site of VT origin in any patient, as previously reported. 7, 9 To achieve the acute procedural end point, patients required extensive ablation with a cumulative radiofrequency time throughout the duration of the study of 148.7±94.6 minutes (range, 25.1-370.4 minutes) in the ENDO-EPI group versus 80.6±88.3 minutes (range, 11.2-342 minutes) in the ENDO-only group (P=0.008 for comparison). At the end of the last procedure (Table 2) , VT noninducibility was achieved in 44of 57 (77%) patients; in 5 patients, programmed ventricular stimulation was not performed at the end of the procedure.
A total of 50 patients underwent repeat programmed ventricular stimulation from the ICD (n=48) or with a repeat invasive electrophysiological study (n=2), a median of 3 (25th-75th quartiles=2-4) days after the procedure. Noninducibility at repeat programmed ventricular stimulation study was achieved in 43 of 50 (86%) patients.
Long-Term Follow-Up After the Last Ablation Procedure
Arrhythmia-Free Survival After a mean follow-up of 56±44 months (median, 40 months [range, 1-154 months]), cumulative VT-free survival was 71%. In the 18 patients with recurrence, 9 had only a single episode of VT at a mean 38±41 months with no further episodes, with an additional 31±23 months of follow-up (Figures 5 and 6) . Of the 9 patients with a single recurrence, 5 were continued on their current regimen (4 on β-blockers and 1 sotalol) and 4 either started (2) sotalol, increased (1) sotalol dose, or switched (1) from quinidine to sotalol. There was no significant association between successful ablation outcome and total number of procedures (median, 1.5 [1] [2] (Table 3) .
Use of AADs
At the last follow-up, a total of 39 patients were receiving β-blockers (30) or no drug therapy (9); 21 received either class 1 or 3 AADs sotalol (11 for atrial arrhythmias). Importantly, amiodarone was able to be discontinued after ablation, with only 2 patients having amiodarone restarted for a short time before transplant for refractory right heart failure ( Figure 4) . None of the remaining patients required long-term amiodarone post ablation. Other Outcomes A total of 5 patients had heart (3), heart/liver (1), or heart/kidney (1) transplant at 61.9±61.8 months (median, 41.5; range, 1-154 months) after their last ablation. The indication for heart transplant was refractory heart failure, not refractory ventricular arrhythmias, although 2 of the 5 patients had documented VT recurrence pretransplant and were being treated with amiodarone. Five patients died (age, 51-80 years) during follow-up at an average of 45.7±54.2 months (range, 4.9-154.3 months). The mode of death was nonarrhythmic in all cases.
Procedural Complications
A total of 5 (4%) complications and no deaths occurred with the 121 procedures. Two patients had postprocedural deep venous thrombosis with pulmonary embolism documented at imaging studies. These patients received anticoagulant therapy without recurrence over follow-up. After these 2 thrombotic events, intravenous heparin therapy was routinely used for 48 hours after all pericardial drains were removed. One patient had a late pericardial effusion after an epicardial procedure; this patient did not receive intrapericardial steroids at the end of the procedure. The effusion was not associated with hemodynamic compromise and was drained percutaneously without consequence. One patient had an RV puncture during percutaneous epicardial access that was directed more anteriorly. Because of continued bleeding after percutaneous drainage in the setting of elevated pulmonary artery pressures, the patient underwent surgical repair with 2 sutures used to close the small laceration. At the time of surgical repair, the patient had concomitant epicardial cryoablation targeting the perivalvular epicardium based on unipolar endocardial abnormalities and ECG of induced VT. Repeat programmed ventricular stimulation study after the surgical ablation was negative for inducible VT, and no recurrent VT was observed after 27 months of follow-up. A final patient developed constrictive pericarditis 6 months after repeat epicardial ablation. This patient required multiple passes of the Tuohy needle to obtain epicardial access and had a total of 132 radiofrequency lesions applied to epicardial surface in the process of substrate modification. The patient developed postprocedure pericarditis and ultimately underwent pericardial stripping because of constrictive pericarditis. 17 Although this patient did receive intrapericardial steroids at the end of the procedure, we think that administration of intrapericardial triamcinolone (2-3 mg/kg) is important to minimize the risk of postprocedure pericarditis; of note, this complication has not been observed in any other patient.
Discussion
This study describes our institutional experience with radiofrequency catheter ablation of VT in ARVC. It documents the long-term outcomes of ENDO with or without adjuvant EPI substrate ablation and subsequent use of AAD therapy in a large cohort of patients with the longest follow-up to date (>4 years on average). The main findings are that ENDO with adjuvant EPI substrate modification when indicated (ie, recurrent VT or persistent inducibility after ENDO-only ablation) provides excellent long-term arrhythmia-free survival, with elimination of VT in the majority of cases and achievement of VT control with infrequent or single isolated recurrent episodes in most of the remaining patients. Importantly, this arrhythmia control was achieved without requiring long-term AAD therapy treatment with amiodarone. In fact, AAD therapy with the exception of β-blockers is uncommonly required in the vast majority of patients unless atrial arrhythmias are also being managed after ablation.
The clinical management of recurrent VT in the setting of ARVC without ablation can be challenging. 16, 17 The efficacy of AADs drug therapy is limited, with amiodarone being the only drug with a demonstrated benefit in the most recent report from the multicenter North American ARVC registry. 4 Given the young age of most ARVC patients, long-term treatment with amiodarone is an unattractive option because of the substantial and time-dependent risk of end-organ toxicity with this drug. 18 In addition, the degree of long-term arrhythmia control with amiodarone is unknown; studies evaluating AADs to treat VT in ARVC have limited follow-up. 4 Of note, none of the 39 patients who underwent ENDO and adjuvant EPI substrate ablation in our series required long-term amiodarone to achieve VT control making us optimistic that this drug can be avoided in most ARVC patients with VT by successful ablation.
Prior studies evaluating the benefit of radiofrequency catheter ablation of VT in the setting of ARVC have reported only shortand mid-term outcomes in relatively small series of patients frequently combining the results from multiple centers. 5, [9] [10] [11] [12] The cumulative evidence arising from such studies and now our own large single-center experience suggest that an ENDO and EPI substrate-based ablation strategy is important for optimizing management of recurrent VT in patients with ARVC.
We think that the importance of an aggressive and comprehensive ENDO substrate modification as part of the overall strategy should be emphasized. Our study supports the notion that ENDO-only ablation may still provide long-term benefit in selected ARVC cases, as the long-term results were achieved with more than one third of patients undergoing ENDO-only procedures. In our experience, ENDO ablation is particularly important to target the most basal aspect of the typical ARVC perivalvular substrate, which cannot be fully addressed with EPI ablation because of the presence of major coronary vessels and fat (Figure 1 ). Importantly, in this study, we reserved EPI ablation only to patients who still had spontaneous or inducible VT after extensive ENDO ablation. Currently, this EPI ablation is typically performed at the same setting. As such, ENDO ablation always represented an important aspect of our procedure and preceded EPI ablation. Therefore, the results of our study do not support a first-line EPI-only ablation approach in patients with ARVC, although adjuvant EPI ablation is often required to achieve long-term VT control. Furthermore, as indicated, 3 of the 5 total major complications occurring in our study were related to intrapericardial access and epicardial ablation. This is in line with the findings by Philips et al 11 in the Johns Hopkins ARVD registry, in which the majority of procedural complications were related to EPI mapping and ablation. These data emphasize the importance of performing ENDO ablation first and proceeding to EPI ablation when inducible VT persists to minimize procedural risks.
Given the exceptionally high VT burden in this patient population, with a median of 4 (and ≤14) distinct clinical/inducible VTs per patient, it is important to emphasize the relevance of a comprehensive and extensive substrate-based ablation strategy that incorporates ENDO and, if still inducible, EPI ablation to achieve the long-term VT control that is reported in the present study. These data, over a >10-year experience with EPI VT ablation, have also directed us to be more comprehensive in the extent of substrate ablation particularly whenever epicardial access is obtained. This was done even more aggressively as our clinical experience evolved to try to minimize the need for repeat ablation procedures that were initially commonly observed. It should be emphasized, however, that our strategy of performing noninvasive programmed stimulation before discharge and bringing patients back to the electrophysiology laboratory if inducible VT is found is still advocated. Early repeat ablation to minimize the potential for late adhesion formation that may limit accessibility is advisable.
Other Observations
Remarkably, 2 patients in our study developed a deep venous thrombosis with pulmonary embolism after the procedure.
The thromboembolic events may be related to a prothrombotic state associated with the venous stasis because of the underlying significant RV dysfunction. After these events, we have changed our approach including postprocedural therapeutic anticoagulation with heparin in every ARVC patient undergoing catheter ablation for at least 48 hours without further recurrence of deep venous thrombosis or venous thromboembolism.
Study Limitations
This was an observational study summarizing a single-center experience spanning >15 years. The choice for the specific ablation approach (ie, ENDO-only versus ENDO-EPI) was not randomized and, as expected, the acute ablation end points evolved over the multiyear study period. However, given the single center nature of the study, the ablation approaches and protocols adopted were uniform. In this regard, decision to perform ENDO-EPI mapping and ablation was driven by 2 criteria, namely (1) persistent VT inducibility after ENDO ablation and (2) VT recurrence after ENDO ablation. None of the patients included in our series had prior cardiac surgery, and other criteria such as ECG features suggesting an EPI origin of the VT were not used to decide to proceed with an EPI approach. Patients, who underwent ENDO-only ablation, were enrolled earlier in the experience and, as a result, also had a longer follow-up, which may potentially act as a bias. In addition, year of enrollment may have influenced the decision to perform EPI ablation, and our threshold for proceeding with an EPI ablation clearly was lower since 2003. Those patients, who had their ablation before 2003, were more likely to experience a clinical recurrence and then have persistent inducible VT, whereas those patients with ablation since 2003 had an EPI ablation if they had inducible VT after extensive ENDOonly ablation before a clinical recurrence. Detailed data on how device were programmed in the individual patients were not available; in this regard, programming may have changed over the years based on findings and results at repeat ablation procedures. However, as mentioned, device programming was uniform in both the ENDO-only and ENDO-EPI groups and always included a VT zone able to detect (and treat if still inducible) the slowest clinical and induced VT; the effect of additional AAD therapy on cycle length slowing was also taken into account to avoid underdetection of VT. Because any sustained VT episode was counted as a recurrence in our study, we feel that our relatively conservative device programming (to detect and potentially treat also slow VTs) further strengthens the value of ablative therapy in our patients-in fact, no VT at all was observed in >70% of cases, and a dramatic reduction of number of VT episodes was observed in most of the remaining patients. Given the small number of events, we could not perform multivariable analysis with the current population, which might not have sufficient power to show independent predictor(s) of outcomes. Tissue characterization with histology and genetic testing were not available in all patients, although each patient had definite diagnosis of ARVC according to the original and revised Task Force criteria.
2,13
Conclusions
ENDO and adjuvant EPI substrate ablation of VT in ARVC provides excellent long-term arrhythmia-free survival. The majority of patients have complete VT control, and most of the remaining patients have a dramatically improved arrhythmiafree survival without amiodarone therapy and limited need for AADs. These data support the concept that an aggressive ablation approach with ENDO and, if needed, EPI VT ablation and substrate modification may result in long-term control of recurrent VT in the setting of ARVC.
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